← All trials
NCT06158698
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 14, 2023
- Primary completion
- May 2, 2026
- Completion date
- May 2, 2028
- First posted
- Dec 6, 2023
- Last posted
- Dec 6, 2023
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MilanLead sponsor
- Mario Negri InstituteCollaborator
- European UnionCollaborator
- Government of ItalyCollaborator
- University of Milano BicoccaCollaborator
- Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, MilanoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.